Theriva Biologics, Inc. Indefinite-lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure
Theriva Biologics, Inc. (TOVX) had Indefinite-lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure of $18.60 million as of 2024-09-30, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Net Asset (Liability)
us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure · last filed 2026-03-12
- 2024-09-30: Indefinite-lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure $18.60M.
| Period end | Indefinite-lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure |
|---|---|
| 2024-09-30 | $18.60M 10-K · filed 2026-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |